Treating mild to moderate hypertension: cost-effectiveness and policy implications

Area of Science:

• Cardiovascular Medicine
• Health Economics
• Public Health Policy

Background:

• Major clinical trials in the 1980s sparked debate on hypertension treatment costs and benefits.
• Existing cost-effectiveness analyses for antihypertensive therapy are outdated and require reassessment.

Purpose of the Study:

• To re-examine the benefits of treating mild to moderate hypertension using pooled clinical trial data.
• To evaluate the cost-effectiveness of antihypertensive therapy in terms of quality-adjusted life years (QALYs).

Main Methods:

• Utilized actuarial methods and health state utility estimates.
• Calculated QALY gains and cost-effectiveness ratios for lifelong hypertension treatment.
• Analyzed data based on age, gender, and diastolic blood pressure (DBP).

Main Results:

• Lifelong treatment yielded QALY gains of 1.8-11.5 months for men and 2.5-11.3 months for women.
• Cost-effectiveness ratios varied widely, from $30,200 to $547,700 per QALY gained (1988 NZD, 5% discount rate).
• Adverse effects of drug treatment outweighed benefits in certain patient groups, indicating a net negative QALY impact.

Conclusions:

• The cost-effectiveness of treating mild to moderate hypertension is highly variable and depends on patient demographics and DBP.
• Findings suggest potential negative impacts of antihypertensive drug therapy for some individuals.
• Results have significant implications for healthcare resource allocation and clinical practice guidelines.